Conference Program Home
  My Program

All Times EDT

Abstract Details

Activity Number: 53 - Considerations in Selection of the Appropriate Intercurrent Event Strategies for Estimands: Hypothetical vs. Composite vs. Treatment Policy
Type: Topic Contributed
Date/Time: Sunday, August 7, 2022 : 4:00 PM to 5:50 PM
Sponsor: Biopharmaceutical Section
Abstract #322218
Title: Hypothetical Conversations: Which Estimand Strategies Are Clinically Relevant When Trial Participants Do Not Follow Clinically Relevant Protocol Guidelines?
Author(s): Bohdana Ratitch* and Katrin Roth
Companies: Bayer Inc., Canada and Bayer
Keywords: estimand; treatment policy strategy; composite strategy; hypothetical strategy; intercurrent events
Abstract:

The ICH E9 R1 introduced five strategies for addressing intercurrent events providing a framework for a nuanced consideration of how to account for a confounding impact of post-randomization events on estimation of the treatment effects. Among the five strategies, the treatment policy, composite, and hypothetical are potentially the most widely applicable. In practice, there sometimes is an impression of a foregone conclusion that the treatment policy strategy is the most desirable and robust. Yet, appropriateness of all strategies should be evaluated equally carefully based on clinical relevance, ability to align the chosen strategy with a robust estimator, and feasibility of collecting sufficient and high-quality data for estimation. In this presentation, we will discuss several aspects and examples of intercurrent events that should be considered to evaluate clinical relevance of the estimand strategies. We will highlight the underlying assumptions of the three strategies under which the estimated treatment effects would be expected to be generalizable to future clinical practice. We will also discuss challenges with estimators that may arise under each of the three strategies.


Authors who are presenting talks have a * after their name.

Back to the full JSM 2022 program